Abstract 125: Fewer Hospitalizations And Emergency Room Visits With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor Or Angiotensin-Receptor Blocker In A Retrospective Claims-Based Study Of Patients With Heart Failure [Session Title: Poster Session AM]
Conclusions: Based on a real-world sample of patients with HFrEF, those initiated with SAC/VAL ≤12 months following US market approval experienced fewer monthly hospitalizations and ER visits compared to ACEI/ARB, and no difference in ambulatory visits. Lower risk of hospitalization after initiating SAC/VAL, rather than using ACEI/ARB, is important since HF hospitalization was previously associated with higher 30-60 day mortality and readmission rate.
Source: Circulation: Cardiovascular Quality and Outcomes - Category: Cardiology Authors: Albert, N. M., Swindle, J. P., Buysman, E. K., Chang, C. Tags: Session Title: Poster Session AM Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diovan | Emergency Medicine | Enalapril | Endocrinology | Heart | Heart Failure | Managed Care | Medicare | Study